COL-118 (sansrosa) confirmed Phase 2 in 2007

Written by on January 8, 2007 in Sansrosa with 0 Comments

Collagenex has confirmed that sansrosa (now called COL-118) is due to move from Phase 1 to Phase 2 some time in 2007. This confirms that COL-118 is still several years away from becoming generally available:

From: Collagenex Pharmaceuticals CEO Speaks About His Company, Jan 8, 2007.

In addition to that, we also have a compound, which is undisclosed at the moment, but referred to as COL-118, that has been targeted for erythema (the redness that is associated with rosacea and acne). That drug will move from Phase I into Phase II during 2007. I think it’s strategically very important for CollaGenex to continue to leverage our platform technologies to give us clearly differentiated products. All three of the products I have referred to are first in class. Oracea is the first systemic treatment labeled for the treatment of rosacea. Incyclinide will be the first significant new chemical entity, if we are successful in getting approval, in the treatment of acne since Accutane. COL-118 will also be a first as there is currently no product specifically and exclusively indicated for the treatment of redness associated with erythema.

Related Articles:

Read more about: Sansrosa

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.